Cargando…
Interleukin-34 cancels anti-tumor immunity by PARP inhibitor
OBJECTIVE: Breast cancer susceptibility gene 1 (BRCA1)-associated ovarian cancer patients have been treated with A poly (ADP-ribose) polymerase (PARP) inhibitor, extending the progression-free survival; however, they finally acquire therapeutic resistance. Interleukin (IL)-34 has been reported as a...
Autores principales: | Nakamura, Takayoshi, Kajihara, Nabeel, Hama, Naoki, Kobayashi, Takuto, Otsuka, Ryo, Han, Nanumi, Wada, Haruka, Hasegawa, Yoshinori, Suzuki, Nao, Seino, Ken-ichiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157335/ https://www.ncbi.nlm.nih.gov/pubmed/36603850 http://dx.doi.org/10.3802/jgo.2023.34.e25 |
Ejemplares similares
-
Interleukin-34 Limits the Therapeutic Effects of Immune Checkpoint Blockade
por: Hama, Naoki, et al.
Publicado: (2020) -
Interleukin-34 Limits the Therapeutic Effects of Immune Checkpoint Blockade
por: Hama, Naoki, et al.
Publicado: (2022) -
Bromodomain-containing protein 4 regulates interleukin-34 expression in mouse ovarian cancer cells
por: Han, Nanumi, et al.
Publicado: (2020) -
An optimized protocol for patient-derived xenograft in humanized mice to evaluate the role of IL-34 in immunotherapeutic resistance
por: Han, Nanumi, et al.
Publicado: (2021) -
A mechanism of IL-34-induced resistance against cytotoxic anti-cancer therapies such as radiation by X-ray and chemotherapy by Oxaliplatin
por: Han, Nanumi, et al.
Publicado: (2023)